Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus

Journal of Gene Medicine

Volumn 12, Issue 8, 2010, Pages 681-692

  Kubo, Shuji ^a   Kawasaki, Yoshiko ^a   Yamaoka, Norie ^a   Tagawa, Masatoshi ^b   Kasahara, Noriyuki ^c   Terada, Nobuyuki ^a   Okamura, Haruki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Malignant mesothelioma; Molecular imaging; Oncolytic adenovirus; Suicide gene therapy

Indexed keywords

GANCICLOVIR; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MIDKINE; ONCOLYTIC ADENOVIRUS; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CELL KILLING; CYTOLYSIS; CYTOMEGALOVIRUS; DRUG EFFICACY; FEMALE; FLUORESCENCE IMAGING; GENE EXPRESSION PROFILING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CYTOKINES; GENETIC VECTORS; HUMANS; INJECTIONS; MESOTHELIOMA; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; SIMPLEXVIRUS; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS; SIMPLEXVIRUS;

EID: 77956646669     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1486     Document Type: Article

References (38)

1. Ismail-Khan R, Robinson LA, Williams CC Jr, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006; 13: 255-263.
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-2090.
3. van der Most RG, Robinson BW, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther 2006; 13: 897-904.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
5. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
6. Nelson DJ, Robinson BW, Allan J, van der Most R. Gene therapy of mesothelioma. Expert Opin Biol Ther 2005; 5: 1039-1049.
7. Albelda SM, Wiewrodt R, Sterman DH. Gene therapy for lung neoplasms. Clin Chest Med 2002; 23: 265-277.
8. Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453.
9. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
10. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008; 15: 877-884. (Pubitemid 351791475)
11. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204: 127-143.
12. Li YS, Milner PG, Chauhan AK, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 1990; 250: 1690-1694.
13. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 1991; 177: 652-658.
14. Mashour GA, Ratner N, Khan GA, et al. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20: 97-105.
15. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57: 1814-1819. (Pubitemid 27199678)
16. Owada K, Sanjo N, Kobayashi T, et al. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 1999; 73: 2084-2092.
17. Qi M, Ikematsu S, Ichihara-Tanaka K, et al. Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by midkine. J Biochem 2000; 127: 269-277.
18. Kojima S, Inui T, Muramatsu H, et al. Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem Biophys Res Commun 1995; 216: 574-581.
19. Kadomatsu K, Hagihara M, Akhter S, et al. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997; 75: 354-359.
20. Miyauchi M, Shimada H, Kadomatsu K, et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 1999; 90: 469-475.
21. Aridome K, Tsutsui J, Takao S, et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655-661.
22. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 2000; 124: 848-852.
23. Garver RI, Jr., Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993; 9: 463-466.
24. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584-1590. (Pubitemid 24302978)
25. Kaname T, Kadomatsu K, Aridome K, et al. The expression of truncated MK in human tumors. Biochem Biophys Res Commun 1996; 219: 256-260.
26. Maeda S, Shinchi H, Kurahara H, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 2007; 97: 405-411.
27. Tsutsui J, Kadomatsu K, Matsubara S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281-1285. (Pubitemid 23097103)
28. Fiegel HC, Kaifi JT, Wachowiak R, et al. Midkine is highly expressed in neuroblastoma tissues. Pediatr Surg Int 2008; 24: 1355-1359.
29. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
30. Kubo S, Seleme MC, Soifer HS, et al. L1 retrotransposition in nondividing and primary human somatic cells. Proc Natl Acad Sci USA 2006; 103: 8036-8041.
31. Adusumilli PS, Chan MK, Chun YS, et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006; 5: 48-53.
32. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999; 59: 410-413.
33. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-8750.
34. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 2003; 63: 8366-8376.
35. Barton KN, Paielli D, Zhang Y, et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13: 347-356.
36. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10: 649-657.
37. Zhu ZB, Makhija SK, Lu B, et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol 2006; 1: 701-711. (Pubitemid 47163960)
38. Fukazawa T, Matsuoka J, Naomoto Y, Maeda Y, Durbin ML, Tanaka N. Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy. Cancer Res 2008; 68: 7120-7129.